GHIF Leads €16 Million Series B Financing for Univercells

Investment proceeds will support commercialization of the company’s breakthrough biologics manufacturing technology Univercells SA (‘Univercells’) and Global Health Investment Fund (‘GHIF’) are pleased to announce the closing of a €16 million ($18.8 million) Series B equity financing. Investment proceeds will support the continued development of Univercells’ game-changing biomanufacturing technology, which has the potential to dramatically [...]

By |2018-07-16T15:49:44+00:00July 16th, 2018|Uncategorized|0 Comments
Read More

GHIF Leads €10 Million Series C Financing for Themis Bioscience

  Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline Proceeds will support the further development of the company's chikungunya vaccine candidate VIENNA - January 4, 2018 - Themis announced today the close of a Series C financing round totaling EUR 10 million. Global Health Investment Fund (GHIF), a New York-based impact investment firm focused [...]

By |2018-02-23T14:44:40+00:00January 4th, 2018|Uncategorized|0 Comments
Read More

Important Information

This website does not constitute an offer or solicitation with respect to interests in GHIF or any other securities. Offers and sales of interests in GHIF have not been and will not be registered under the U.S. Securities Act and such interests may be sold only to accredited investors. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of an investment in GHIF or the accuracy or adequacy of this website. Interests in GHIF are not subject to the protections of the U.S. Investment Company Act of 1940.
Copyright 2016 Global Health Investment Advisors, LLC | All Rights Reserved | Powered by WordPress | Theme Fusion
Go to Top